Three categories of immunotoxic effects are identified: direct immunotoxicity, hypersensitivity, and autoimmunity. Direct immunotoxicity consists of immunosuppression and immunostimulation. Total abrogation of the immune response (immunosuppression) results in more frequent, severe, and often atypical and relapsing infections and lymphomas. Immunostimulation is associated with febrile reactions, the induction/facilitation of autoimmune diseases and allergic reactions to unrelated allergens, and impaired hepatic drug biotransformation. Hypersensitivity is manifested by a variety of symptoms involving either antigen-specific or non-antigenspecific humoral and cellular adverse responses. Autoimmune reactions are divided into organ-specific and systemic reactions. Because of the involvement of many redundant mechanisms, it is difficult to predict responses of the immune system to a given immunotoxic injury. In laboratory animals, histologic but also functional changes are necessary to show evidence of and to predict such adverse responses.
INTRODUCTION
Although immunotoxicology is a young disciplineless than 20 years of age-significant progress has been made in describing and predicting the immunotoxic effects of a wide variety of chemicals, including medicinal products, pesticides, industrial chemicals, airborne pollutants, cosmetics, and food additives, essentially in laboratory animals (5) . Immunotoxic effects are divided into 3 distinctive categories: direct immunotoxicity, hypersensitivity, and autoimmunity. Each effect category is associated with markedly different health consequences, mechanisms, and modalities of preclinical and clinical evaluation (4) . DIRECT 
IMMUNOTOXICITY
Direct immunotoxicity refers to quantitative, ie, dosedependent, changes of an otherwise (qualitatively) normal immune response that can be either impaired (immunosuppression or immunodepression) or enhanced (immunostimulation).
Immunosuppression
The major adverse responses to immunosuppression are an increased susceptibility of the immunocompromised host to microbial invaders and more frequent neoplasias, in particular lymphomas, as unequivocally shown in both transplant and cancer patients treated with potent immunosuppressive drugs (14) . Marked immunosuppression, or total abrogation of the immune response, often results in more frequent and severe, usually relapsing, and sometimes atypical (opportunistic) infections. Even though it remains to be confirmed whether mild to moderate impairment of the immune responsiveness (immu-nodepression) can actually lead to more frequent infections, patients with rheumatoid arthritis or other autoimmune diseases that are on low-dose immunosuppressive treatment regimens have been reported to develop clinically similar, although less frequent, infectious complications.
The mechanisms leading to the increased susceptibility of immunocompromised patients to infectious micro-organisms (10) include antigen-specific effector mechanisms, such as antibody and T-lymphocyte responses, and nonspecific mechanisms, such as natural killer cell activity, phagocytosis, and complement-mediated lysis. The clinical experience gained from patients with primary (congenital) or secondary (acquired) immune defects has shown that immune competence relies on a redundancy of mechanisms, so that only profound defects in a given effector mechanism can result in overt infections. To some extent, the pattern of infectious complications is dependent on the type of the immune defect in a given patient. However, the combination of several less severe immune defects may also result in infectious complications. Because of the redundancy of the mechanisms involved, it is usually difficult to predict whether and to what extent functional immune changes induced by drug treatment or chemical exposure are likely to result in increased susceptibility to infections in a given individual or group of individuals. This challenge is undoubtedly a major one for immunotoxicologists, because they are expected to provide the scientific rationale for immunotoxicity risk assessment (11) . A good example among the few attempts at risk assessment is the immunotoxicity risk assessment of ultraviolet light exposure based on animal findings, in particular resistance to experimental infection and functional immune changes, and estimated human exposure (12) . Because of the lack of human data, risks can rarely be assessed, and when the use of experimental infections is impossible, as is increasingly the case in many countries, no reliable prediction of the actual risk of infectious complications can be made at the present time.
The second major adverse response to immunosuppression is the development of neoplasias, in particular lymphomas. Nearly every immunosuppressive drug in clinical use today has been shown to be associated with more frequent lymphomas. Lymphomas have also been reported in a few patients on low-dose immunosuppressive drug therapy for autoimmune diseases. In contrast, there is limited evidence that other types of neoplasias are more frequent in patients exposed to therapeutic or environmental immunotoxicants, with the exception of virus-associated skin cancers. The question of whether pesticides cause more frequent lymphomas is still debated, but most pesticides have not been shown to be overtly immunotoxic in human beings (16) .
Although uncertainties remain regarding the mechanisms involved in the induction of immunosuppressionassociated lymphomas, latent viral infections are considered to be a major cause of lymphomas in immunocompromised patients (2) . Immunocompromised Epstein-Barr virus (EBV)-infected patients develop lymphomas as a result of impaired T-lymphocyte control of EBV proliferation, which could explain why cessation of therapeutic immunosuppression in certain patients may result in full recovery.
Immunostimulation
The adverse responses to immunostimulation are less clearly established, but clinical experience is rapidly being gained with the introduction of recombinant cytokines into the clinical setting. These adverse responses include febrile reactions, more frequent autoimmune and immune allergic reactions, and the inhibition of cytochrome P450 biotransformation pathways.
Febrile reactions refer to flulike reactions when these are mild (38-38.5°C), with chills, arthralgias, and malaise, and when they are easily prevented or corrected by antipyretic drugs, such as paracetamol (acetaminophen). These reactions can also refer to acute cytokine syndromes when they are severe, with diarrhea, chest pain, hypotension, cardiovascular collapse, or cardiac ischaemia and neurologic disorders, such as tremor, confusion, and seizures, and are treatment limiting (13) . The activation of macrophages, either direct activation by microbial immunostimulating drugs or indirect activation, in particular through the release of y-interferon, is the most likely mechanism. Hyperpyrexia is related to the release of interleukin-1, tumor necrosis factor a, and/or eicosanoids by activated macrophages.
The induction of autoimmune diseases, in particular autoimmune thyroiditis and lupus erythematosus, is a relatively frequent finding in patients treated with recombinant cytokines. Autoantibodies and/or autoimmune thyroiditis have been described in over 10% of patients treated with interleukin-2 or the interferons (14) . Recombinant cytokines augment the expression of major histocompatability complex class II antigens on certain cells, such as thyroid cells, which can thus behave as antigen-presenting cells (8) .
The facilitation of hypersensitivity reactions to unrelated allergens is another potential although widely unnoticed complication of immunostimulation, in particular in relation to immunostimulating drugs (13) . Postmarketing drug surveillance data nevertheless showed that the introduction of drugs with immune-enhancing properties can trigger asthma, urticaria, and eczema and even anaphylactic shock in some patients.
The inhibition of cytochrome P450 biotransformation pathways is the last but not least potential complication of immunostimulation. Bacillus calmette-guerin (BCG) and a-interferon have been shown to influence negatively the pharmacokinetics of theophylline, antipyrine, and/or caffeine in healthy volunteers and in patients, whereas conflicting results were observed with influenza and tetanus vaccines. The molecular mechanism of cytochrome P450 downregulation by immunostimulating agents is relatively well understood (9) . Interferons inhibit protein synthesis, and downregulation of cytochromes P450 was suggested to involve alterations in apoprotein synthesis or breakdown but not a general decrease in the synthesis of hepatic microsomal proteins. HYPERSENSITIVITY Hypersensitivity reactions induced by medicinal products and chemicals are relatively common but fortunately mild in the majority of cases, although they can sometimes be life threatening (6) . Overall, hypersensitivity reactions can be divided into 2 major categories: immunemediated and non-immune-mediated reactions.
Immune-mediated hypersensitivity reactions are often referred to as allergic or immunoallergic reactions. The Gell and Coombs classification (3) into 4 pathophysiological types is seldom relevant, because a number of other mechanisms are also involved, sometimes simultaneously. Skin (eg, contact dermatitis) and respiratory (eg, asthma) allergic reactions are the most frequent clinical complaints. Our current understanding of critical mechanisms, such as the regulation of the immune response involving TH, and TH2 lymphocytes or the molecular basis of drug and chemical allergenicity, is very limited; therefore, few reliable diagnosis tools and predictive animal models are available.
In addition, non-immune-mediated or pseudoallergic reactions seem to be frequent. Intolerance to aspirin and nonsteroidal anti-inflammatory agents, dyes, and food additives are typical examples (7) . Although, strictly speaking, pseudoallergic reactions cannot be considered immunotoxic effects, the same mediators, such as histamine or components of the complement cascade, are involved, accounting for many clinical similarities between immunoallergic and pseudoallergic reactions.
AUTOIMMUNITY
A number of xenobiotics have been suggested to induce autoimmune diseases, even though documented case reports are rare (1) . In addition, chemicals such as mercuric chloride that are commonly used to induce autoimmune reactions either in vitro or in genetically prone laboratory animals have rarely, if ever, been conclusively shown to induce autoimmune diseases in humans.
Autoimmune reactions are divided into organ-specific and systemic reactions. The most frequent organ-specific autoimmune reactions in relation to drug treatment or chemical exposure are autoimmune hemolytic anemia and myasthenia, although these reactions are quite infrequent. Systemic reactions include primarily the lupus syndrome and scleroderma. Organ-specific autoimmune reactions are clinically and biologically very similar to the corresponding spontaneous diseases, whereas systemic reactions are often markedly dissimilar, which strongly suggests that the mechanisms of organ-specific and systemic autoimmune reactions are different. Even though chemically induced autoimmune reactions are seemingly rare-less than 0.2% of case reports recorded by the French network of Postmarketing Drug Surveillance (15)-they may nevertheless affect large segments of the population, as shown by the Spanish toxic oil syndrome and eosinophilia-myalgia associated with L-tryptophan, 2 recent epidemics of suspected autoimmune origin.
CONCLUSION
Because of the enormous variety of mechanisms involved and the redundancy of the immune system, it is difficult to predict responses of the immune system to a given (immuno)toxic injury. Previous immunotoxicity studies focused on the identification of histologic changes in the lymphoid organs and functional immune alterations in laboratory animals. This approach proved was very useful for detecting a number of possible or probable immunotoxicants. However, much work remains to be done to evaluate the relevance of observed changes in terms of immunotoxic risk for human beings. Further efforts must be made to collect human data and to understand more completely the mechanisms involved in immunotoxicity.
